Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 726-730, 2017.
Article
em Zh
| WPRIM
| ID: wpr-617789
Biblioteca responsável:
WPRO
ABSTRACT
In recent years, immune therapy for the treatment of cancer has made remarkable progress. The monoclonal antibodies of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In this review, we summarized the current clinical status and future direction of PD-1/PD-L1 in NSCLC.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Oncology
Ano de publicação:
2017
Tipo de documento:
Article